CJ-15314 is under clinical development by HK inno.N and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CJ-15314’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CJ-15314 overview

CJ-15314 is under development for the treatment of rheumatoid arthritis, psoriasis and atopic dermatitis. The drug candidate is administered orally as capsule and topically as ointment. The drug candidate is a new chemical entity and acts by targeting Janus kinase, which is non-receptor tyrosine kinases.

HK inno.N overview

HK inno.N, a subsidiary of Kolmar Korea Co Ltd, is a manufacturer of active pharmaceutical ingredients and prescription drugs. Its product portfolio includes EPOKINE for the treatment of renal anemia, Leukokine to treat neutropenia, Calmtop for the treatment of colorectal cancer, Movealoxin, Cinezolid, Omapone a parenteral nutrition product and Pemta an infusion solution. HK inno.N is headquartered in Seoul, South Korea.

For a complete picture of CJ-15314’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.